BRAF inhibitor + MEK inhibitor
Blocking two consecutive steps in the same relay prevents the pathway from rerouting and reduces side effects.
Dabrafenib-trametinib and encorafenib-binimetinib improved PFS and OS over BRAF inhibitor alone in melanoma and reduced paradoxical MAPK activation (fewer skin cancers). Template for vertical pathway inhibition.
Pages like this
not linked directly; found by shared links- TrialCOMBI-AD
Shares Dabrafenib + trametinib, BRAF, RAS / RAF / MEK / ERK (MAPK), Melanoma.
- ProductBinimetinib
Shares Encorafenib, BRAF, RAS / RAF / MEK / ERK (MAPK), Melanoma.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Dabrafenib + trametinib, Encorafenib, BRAF, Melanoma.
- TrialCOLUMBUS
Shares Encorafenib, BRAF, RAS / RAF / MEK / ERK (MAPK), Melanoma.
- PersonKeith T. Flaherty
Shares Dabrafenib + trametinib, BRAF, Melanoma.
- PersonRené Bernards
Shares Encorafenib, BRAF, Colorectal cancer.
- PersonRyan B. Corcoran
Shares Encorafenib, BRAF, Colorectal cancer.
- TrialBREAKWATER
Shares Encorafenib, BRAF, RAS / RAF / MEK / ERK (MAPK), Colorectal cancer.